Myeloid malignancies are clonal disorders that are characterized by acquired somatic
mutation in hematopoietic progenitors. Recent advances in our understanding of the genetic …

Blood eosinophilia signifies either a cytokine‐mediated reactive phenomenon (secondary)
or an integral phenotype of an underlying haematological neoplasm (primary). Secondary …

Abstract We have identified at (8; 9)(p21-23; p23-24) in seven male patients (mean age 50,
range 32-74) with diverse hematologic malignancies and clinical outcomes: atypical chronic …

Tumor cell proliferation is frequently associated with genetic or epigenetic alterations in key
regulators of the cell cycle. Most known oncogenes and tumor suppressors target entry into …

Myeloid neoplasms and eosinophilia with rearrangements of PDGFRB are uncommon
Philadelphia-negative myeloproliferative neoplasms. Patients are typically male, with …

The year 2008 marks the fifth anniversary since the publication which identified the FIP1L1–
PDGFRA fusion gene in patients with idiopathic hypereosinophilia. With the benefit of time, a …

Myeloproliferative disorders (MPDs) constitute a group of hematopoietic malignancies that
feature enhanced proliferation and survival of one or more myeloid lineage cells. William …

Fusion genes derived from the platelet-derived growth factor receptor beta (PDGFRB) or
alpha (PDGFRA) play an important role in the pathogenesis of BCR-ABL–negative chronic …

Imatinib mesylate (Gleevec) was developed as the first molecularly targeted therapy that
specifically inhibits the BCR–ABL tyrosine kinase activity in patients with Philadelphia …

Chronic myeloid leukemia (CML) is characterized by the presence of at (9; 22)(q34; q11. 2),
which leads to the well‐known BCR–ABL1 fusion protein. We describe a patient who was …